Drug Approval | February 24, 2026
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Patients can now get the starting 2.5 mg dose for $299 per month
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Subscribe To Our Newsletter & Stay Updated
